7 results about "Soft tissue infection" patented technology

The invention relates to tedizolid gel and a preparation method thereof. The tedizolid gel is prepared from the following raw materials and auxiliary materials: an active component, a gel matrix, an alcohol solvent, a bacteriostatic agent, a pH regulator and water, the active component is tedizolid or ester thereof, or pharmaceutically acceptable salt thereof; the gel matrix is carbomer. The tedizolid gel can increase the local tissue free drug concentration of the skin of the bacterial infection part of an organism through transdermal absorption, so that the bacteriostatic activity of the tedizolid gel is better played, the treatment effect on local acute bacterial skin and skin soft tissue infection is improved, and the adverse reaction is reduced.

The application discloses a synergistic bactericidal composition, comprising the following components: a toona sinensis extract: 16-2048 mu g / mL; a macrolide antibiotic: 0.0625-4096 mu g / mL; the bacteria are staphylococcus aureus or methicillin-resistant staphylococcus aureus, and the macrolide antibiotic is erythromycin or azithromycin. The application further discloses a use of the synergistic bactericidal composition in preparation of a medicine for treating skin and soft tissue infections. The composition provided by the application can convert the traditional macrolide antibiotics such as erythromycin and azithromycin which only have a bacteriostatic effect into a preparation which has clear bactericidal activity on staphylococcus aureus and drug-resistant strains thereof. After the toona sinensis extract is combined with the antibiotic, a synergistic effect is exhibited, and the concentration of the toona sinensis extract and the antibiotic required when the toona sinensis extract and the antibiotic are used alone can be greatly reduced.

The invention discloses application of alpha-hederin in preparation of a medicine for preventing or treating staphylococcus aureus infectious diseases, and belongs to the technical field of medicines. The staphylococcus aureus infectious disease is one of skin or soft tissue infection, pneumonia, osteoarthritis, mastitis, enteritis, endocarditis, urinary tract infection and enteritis. The medicine does not have an in-vitro direct sterilization function on sensitive and methicillin-resistant staphylococcus aureus, but can remarkably promote infected cells to remove thalli under a cell infection condition, so that the medicine plays a role in resisting sensitive and methicillin-resistant staphylococcus aureus infection by improving the anti-infection immune level of the cells.

The invention belongs to the technical field of clinical examination and diagnosis, and relates to a molecular marker for diagnosing necrotic soft tissue infection as well as application and a model of the molecular marker. The molecular marker is selected from one or a combination of more of estrone sulfate, 3-hydroxydecanoic acid and N-lactoyl-phenylalanine. The molecular marker, the application and the construction method can be quickly, simply, sensitively and specifically used for early diagnosis of necrotic soft tissue infection.

The application belongs to the technical field of biological medicine, and provides application of ferulic acid in preparation of a photolysis inhibitor of tigecycline and minocycline. The ferulic acid can significantly inhibit degradation of tigecycline or minocycline under light conditions, and further enhance the antibacterial activity of tigecycline or minocycline under light conditions. Compared with the treatment of tigecycline alone, the addition of ferulic acid can significantly enhance the treatment effect of tigecycline or minocycline as an external medicine on skin or soft tissue infection, effectively expand the drug dosage form of tigecycline or minocycline, and provide a safer and more reliable drug preparation for the treatment of complex drug-resistant pathogenic bacterial skin or soft tissue infection.

The present invention relates to peptides, fusion proteins and compositions for inducing an immune response against bacteria. The invention also relates to the treatment or prevention of infections by sepsis-inducing bacteria, and to the treatment and prevention of pathological conditions caused by such bacteria. Such pathological conditions include sepsis, pneumonia, meningitis, endocarditis, enterocolitis, urinary tract infection, soft tissue infection, gastrointestinal tract infection, bloodstream infection, encephalitis, premature delivery and dead delivery.

The invention discloses a synergistic bactericidal composition which comprises the following components: 16 g / mL-2048 g / mL of cortex albiziae extract, 10 g / mL-20 g / mL of plant extract, 10 g / mL-20. The content of the macrolide antibiotics is 0.0625 g / mL to 4096 g / mL; the bacteria are staphylococcus aureus or methicillin-resistant staphylococcus aureus, and the macrolide antibiotics are erythromycin or azithromycin. The invention also discloses application of the synergistic bactericidal composition in preparation of medicines for treating skin and soft tissue infection. According to the composition provided by the invention, macrolide antibiotics, such as erythromycin and azithromycin, which only have a bacteriostatic effect traditionally can be converted into preparations which have definite bactericidal activity on staphylococcus aureus and drug-resistant strains thereof. After the cortex albiziae extract and the antibiotics are combined for use, an extremely strong synergistic effect is shown, and the concentrations required when the cortex albiziae extract and the antibiotics take effect independently can be greatly reduced.